Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px
Organisation › Details

ProBioGen AG

ProBioGen is a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines with applying proprietary technologies to improve product quality and features. Combining both state-of-the-art development services, based on ProBioGen's CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with GMP standards (EMA/FDA). ProBioGen has been operational for almost 30 years. At four locations in Berlin, 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow. *

 

Period Start 2003-07-01 renamed before
  Group Minapharm (Group)
  Predecessor ProBioGen GmbH Produktions- und Entwicklungsgesellschaft für ..mbH
Products Industry recombinant protein production in mammalian cells
  Industry 2 contract manufacturing (biologicals)
Persons Person Hilbrich, Lutz (Droege Investment 202409– CEO of Halix BV before ProBioGen AG + Sanofi China + Boehringer)
  Person 2 Sandig, Volker (ProBioGen 201004 promoted CSO since 2000 at ProBiogGen before Merck US)
     
Region Region Berlin
  Country Germany
  Street 8 Herbert-Bayer-Str.
  City 13086 Berlin
  Tel +49-30-3229-35-100
    Address record changed: 2024-03-20
     
Basic data Employees C: 51 to 100 (2014-09-09)
     
    * Document for »About Section«: ProBioGen AG. (3/13/24). "Press Release: ProBioGen Partners with Mapp Biopharmaceutical, Inc. for Groundbreaking Development of Afucosylated Antibody against Marburg Virus Disease Using GlymaxX Technology". Berlin.
     
   
Record changed: 2024-09-20

Advertisement

Picture biomindz Mainz Biomed LSG Colorectal Cancer Screening 650x200px

More documents for Minapharm (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture biomindz Brand LSG Mainz Place to Biotech 650x300px




» top